- Home
- IMCR vs WLY Comparison
IMCR vs WLY Comparison
Compare IMCR & WLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- WLY
- Stock Information
- Founded
- IMCR 2008
- WLY 1807
- Country
- IMCR United Kingdom
- WLY United States
- Employees
- IMCR N/A
- WLY N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- WLY Books
- Sector
- IMCR Health Care
- WLY Consumer Discretionary
- Exchange
- IMCR Nasdaq
- WLY Nasdaq
- Market Cap
- IMCR 1.5B
- WLY 2.1B
- IPO Year
- IMCR 2021
- WLY N/A
- Fundamental
- Price
- IMCR $32.80
- WLY $43.29
- Analyst Decision
- IMCR Buy
- WLY
- Analyst Count
- IMCR 10
- WLY 0
- Target Price
- IMCR $58.13
- WLY N/A
- AVG Volume (30 Days)
- IMCR 444.9K
- WLY 709.9K
- Earning Date
- IMCR 08-07-2025
- WLY 06-17-2025
- Dividend Yield
- IMCR N/A
- WLY 3.26%
- EPS Growth
- IMCR N/A
- WLY N/A
- EPS
- IMCR N/A
- WLY 1.53
- Revenue
- IMCR $333,581,000.00
- WLY $1,677,609,000.00
- Revenue This Year
- IMCR $26.82
- WLY $1.75
- Revenue Next Year
- IMCR $8.15
- WLY $2.40
- P/E Ratio
- IMCR N/A
- WLY $28.29
- Revenue Growth
- IMCR 25.75
- WLY N/A
- 52 Week Low
- IMCR $23.15
- WLY $36.50
- 52 Week High
- IMCR $41.54
- WLY $53.96
- Technical
- Relative Strength Index (RSI)
- IMCR 51.47
- WLY 56.41
- Support Level
- IMCR $30.76
- WLY $43.05
- Resistance Level
- IMCR $33.95
- WLY $45.64
- Average True Range (ATR)
- IMCR 1.39
- WLY 1.40
- MACD
- IMCR -0.15
- WLY 0.31
- Stochastic Oscillator
- IMCR 43.05
- WLY 74.29
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About WLY John Wiley & Sons Inc.
John Wiley & Sons Inc is one of the world's greatest publishers and a trusted leader in research and learning. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.